Pure Global
NCT06401824

Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

A Single Arm Phase II Study Evaluating Intracranial Efficacy of Sacituzumab Govitecan (SG) With Bevacizumab in Patients With Active, Asymptomatic Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
Maastricht University Medical Center·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
NSCLC Stage IV,Brain Metastases, Adult
Drug/Device/Intervention
Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Maastricht University Medical Center
Location
Amsterdam,Groningen,Maastricht, Netherlands
Timeline & enrollment
Phase
Phase 2
Start date
Jul 01, 2024
End date
Apr 01, 2027
Enrollment
25 participants
Primary outcome

brain metastases overall response rate (ORR)

Summary

This study will evaluate whether the combination of sacituzumab govitecan (SG) and
 bevacizumab will result in shrinkage of brain metastases from patients with non-squamous
 non-small cell lung cancer (NSCLC), with disease progression on chemotherapy and
 immunotherapy.

ICD-10 classifications
Malignant neoplasm: Brain, unspecifiedMalignant neoplasm of brainMalignant neoplasm: Cerebral ventricleMalignant neoplasm: Central nervous system, unspecifiedMalignant neoplasm: Overlapping lesion of brain and other parts of central nervous system
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06401824
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06401824 through Pure Global AI's free database. This Phase 2 trial is sponsored by Maastricht University Medical Center and is currently Not yet recruiting. The study focuses on NSCLC Stage IV,Brain Metastases, Adult. Target enrollment is 25 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.